Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lanthanumcarbonathydrat - tyggetabletter - 750 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

bristol-myers squibb ab - triamcinolonacetonid - injektionsvæske, suspension - 40 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

takeda pharmaceuticals international ag ireland branch - mesalazin - enterodepottabletter - 1200 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aspen pharma trading limited - mivacuriumchlorid - injektionsvæske, opløsning - 2 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

merck sharp & dohme b.v. - pneumokok polysaccharid serotype 1, pneumokok polysaccharid serotype 10a, pneumokok polysaccharid serotype 11a, pneumokok polysaccharid serotype 12f, pneumokok polysaccharid serotype 14, pneumokok polysaccharid serotype 15b, pneumokok polysaccharid serotype 17f, pneumokok polysaccharid serotype 18c, pneumokok polysaccharid serotype 19a, pneumokok polysaccharid serotype 19f, pneumokok polysaccharid serotype 2, pneumokok polysaccharid serotype 20, pneumokok polysaccharid serotype 22f, pneumokok polysaccharid - injektionsvæske, opløsning

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmathen s.a. - travoprost - øjendråber, opløsning - 40 mikrogram/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydrochlorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosuppressiva - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - andre præparater antianemic - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiske midler - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - leukæmi, myeloid, akut - antineoplastiske midler - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).